Previous 10 | Next 10 |
2023-07-28 12:49:08 ET Shares of Reata Pharmaceuticals Inc ( NASDAQ: RETA ) opened more than 50% up this morning after Biogen Inc ( NASDAQ: BIIB ) said it will buy the pharma company for $7.3 billion. Why is Biogen making this acquisition? The all-cash agreement values e...
2023-07-28 07:18:20 ET Biogen Inc. ( NASDAQ: BIIB ) agreed to buy Reata Pharmaceuticals ( NASDAQ: RETA ) for $172.50 per share in cash, or an enterprise value of about $7.3 billion. Reata shares were halted for news pending. Biogen fell 3.6% in premarket tradin...
SKYCLARYS ® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth, adding a highly complementary innovative product in an area...
2023-07-27 06:00:00 ET When you think about biotech leaders, the name Biogen (NASDAQ: BIIB) may come to mind. Over the years, this biotechnology giant built a powerful multiple sclerosis (MS) treatment platform that has brought in billions of dollars in earnings. And earnings growth...
2023-07-26 15:46:00 ET Shares of the brain-health specialist Sage Therapeutics (NASDAQ: SAGE) are having a tough trading session today. Specifically, the biotech's stock was down by approximately 13% on heavy volume as of 2:38 p.m. ET Wednesday afternoon. The spark? Yesterday, ...
2023-07-26 13:36:56 ET Sage Therapeutics ( NASDAQ: SAGE ) lost more than 14% Wednesday to reach the lowest level since November amid investor concerns over its depression therapy, zuranolone, as the FDA is set to decide on its marketing application by early August. In March,...
2023-07-25 18:09:46 ET Typically, when a publicly traded company reports an estimates-beating quarter, its stock price rises in reaction. There are always exceptions, though, and on Tuesday it was Biogen 's (NASDAQ: BIIB) turn to be atypical. After Biogen published second-quarte...
2023-07-25 15:30:45 ET Image source: The Motley Fool. Biogen (NASDAQ: BIIB) Q2 2023 Earnings Call Jul 25, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Biogen (BIIB) Q2 2023 Earnings Call Transcript
2023-07-25 12:43:10 ET Biogen Inc. (BIIB) Q2 2023 Earnings Conference Call July 25, 2023, 8:00 AM ET Company Participants Chuck Triano - Head of Investor Relations Christopher Viehbacher - President and Chief Executive Officer Priya Singhal - Head of Development ...
2023-07-25 10:22:46 ET Summary Biogen, Eisai, and Eli Lilly's Alzheimer's drugs have shown little efficacy, particularly in non-APOE4 carriers. The companies recast the data to suggest non-carriers benefitted more from their drugs, but in reality, non-carriers benefitted least as ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...